We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluating the Link Between Thiazide Medications, the Nervous System, and Diabetes in Individuals With High Blood Pressure

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00353652
First Posted: July 19, 2006
Last Update Posted: December 29, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
Wanpen Vongpatanasin, University of Texas Southwestern Medical Center
July 18, 2006
July 19, 2006
December 2, 2014
December 29, 2014
December 29, 2014
January 2005
January 2013   (Final data collection date for primary outcome measure)
  • Sympathetic Nerve Activity [ Time Frame: Measured at 6 months ]
  • 24-hour Ambulatory Blood Pressure [ Time Frame: Measured at 6 months ]
  • Insulin Sensitivity [ Time Frame: Measured at 6 months ]
  • Forearm Blood Flow [ Time Frame: Measured at 6 months ]
  • Baroreflex Sensitivity [ Time Frame: Measured at 6 months ]
  • C-reactive Protein [ Time Frame: Measured at 6 months ]
  • Inflammatory Cytokines [ Time Frame: Measured at 6 months ]
  • Sympathetic Nerve Activity
  • 24-hour Ambulatory Blood Pressure
  • Insulin Sensitivity
  • Forearm Blood Flow
  • Baroreflex Sensitivity
  • C-reactive Protein
  • Inflammatory Cytokines
  • Arterial stiffness (all measured at the end of each treatment program)
Complete list of historical versions of study NCT00353652 on ClinicalTrials.gov Archive Site
  • Electrolytes [ Time Frame: Measured at 6 months ]
  • Body Weight [ Time Frame: Measured at 6 months ]
  • Electrolytes
  • Body weight (both measured at the end of each treatment program)
Not Provided
Not Provided
 
Evaluating the Link Between Thiazide Medications, the Nervous System, and Diabetes in Individuals With High Blood Pressure
Neural Mechanisms of Thiazide-induced Insulin Resistance
Thiazide medications are often prescribed for individuals with high blood pressure, but research has shown that they may increase an individual's risk of developing diabetes. While it is unknown exactly how thiazide causes this response, it is likely that the nervous system is somehow involved. This study will evaluate the role of the nervous system in sugar metabolism, as well as determine the effect of thiazide and other medications on individuals with high blood pressure.

Thiazide medications, including chlorthalidone, are commonly prescribed for individuals with high blood pressure because they are inexpensive, effective at lowering blood pressure, and able to reduce the risk of heart failure and stroke. Despite these advantages, research has shown that thiazide medications may increase an individual's risk of developing diabetes. The exact mechanism that causes this remains unknown. Thiazide appears to increase sympathetic nervous system activity, thereby decreasing glucose reuptake and metabolism by skeletal muscle tissues. In turn, this tends to contribute to glucose intolerance and the development of diabetes. More research, however, is needed to confirm this link. Spironolactone, another blood pressure medication, does not pose the same risk for developing diabetes and may prove beneficial as a primary treatment for high blood pressure. The purpose of this study is to determine the role of the sympathetic nervous system in glucose metabolism in individuals with high blood pressure, as well as compare the effectiveness of thiazide, spironolactone, and other antihypertensive medications in reducing blood pressure. Results from this study may initiate the development of future clinical trials involving spironolactone as a primary treatment for reducing blood pressure.

This study will enroll individuals with high blood pressure. Participants will be assigned to one of eight treatment groups. Depending on the assigned group, participants will receive chlorthalidone, spironolactone, quinapril, irbesartan, eplerenone, or a combination of these drugs, with or without placebo. Participants will attend four to six study visits over a period of 16 to 28 weeks. All participants will attend a baseline study visit, which will include a physical examination, a medical history review, vital sign measurements, and blood and urine collection. Small electrodes will be used to measure muscle nerve activity. In addition, blood pressure will be monitored continuously for 24 hours prior to the start of the study. Depending on the assigned treatment group, study visits may include blood collection, blood pressure monitoring, an electrocardiogram (ECG) to record heart activity, nerve function monitoring, and/or plasma volume measurements. Participants' baroreflex sensitivity may also be measured by monitoring nerve ending responses within the heart and blood vessels. Insulin sensitivity will be measured with a glucose tolerance test and by evaluating skeletal muscle glucose uptake.

Interventional
Phase 4
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Prevention
Hypertension
  • Drug: Chlorthalidone
    12.5-25 mg taken orally, once daily
  • Drug: Spironolactone
    50-75 mg taken orally, once daily
  • Drug: Eplerenone
    50-100 mg taken orally, once daily
  • Drug: Quinapril
    20 mg taken orally, once daily
  • Drug: Irbesartan
    150 mg taken orally, once daily
  • Experimental: 1A
    Interventions:
    • Drug: Chlorthalidone
    • Drug: Spironolactone
  • Experimental: 1C
    Interventions:
    • Drug: Quinapril
    • Drug: Irbesartan
  • Experimental: 2
    Intervention: Drug: Eplerenone
  • Experimental: 3
    Interventions:
    • Drug: Chlorthalidone
    • Drug: Spironolactone

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
176
January 2013
January 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Untreated stage 1 primary hypertension (systolic blood pressure between 140 to 159 mm Hg and diastolic blood pressure between 90 to 99 mm Hg)

Exclusion Criteria:

  • Cardiopulmonary disease, as determined by medical history or by physical examination
  • Serum creatinine greater than or equal to 1.5 mg/dL
  • Diabetes mellitus or other systemic illness
  • Left ventricular hypertrophy by echocardiography or ECG
  • Hypersensitivity to chlorthalidone, spironolactone, eplerenone, angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blocker, insulin, Evans blue dye, or clonidine
  • History of substance abuse (other than tobacco)
  • History of gouty arthritis
  • History of ACE inhibitor-induced cough or angioedema
  • Evidence of secondary hypertension
  • Pregnant
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00353652
413
R01HL078782-02 ( U.S. NIH Grant/Contract )
Yes
Not Provided
Not Provided
Wanpen Vongpatanasin, University of Texas Southwestern Medical Center
University of Texas Southwestern Medical Center
National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigator: Wanpen Vongpatanasin, MD University of Texas, Southwestern Medical Center at Dallas
University of Texas Southwestern Medical Center
December 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP